Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:PCRX
  • CUSIP: 69512710
  • Web:
  • Market Cap: $1.91047 billion
  • Outstanding Shares: 40,093,000
Average Prices:
  • 50 Day Moving Avg: $46.95
  • 200 Day Moving Avg: $45.52
  • 52 Week Range: $29.95 - $58.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 180.37
  • P/E Growth: -75.15
Sales & Book Value:
  • Annual Revenue: $280.18 million
  • Price / Sales: 6.97
  • Book Value: $6.76 per share
  • Price / Book: 7.20
  • EBIDTA: ($31,100,000.00)
  • Net Margins: -19.26%
  • Return on Equity: -7.71%
  • Return on Assets: -4.05%
  • Debt-to-Equity Ratio: 0.98%
  • Current Ratio: 9.82%
  • Quick Ratio: 9.15%
  • Average Volume: 572,294 shs.
  • Beta: 2.17
  • Short Ratio: 5.98
Frequently Asked Questions for Pacira Pharmaceuticals (NASDAQ:PCRX)

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. The business earned $69.30 million during the quarter, compared to analysts' expectations of $70.30 million. Pacira Pharmaceuticals had a negative net margin of 19.26% and a negative return on equity of 7.71%. The business's revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $0.15 earnings per share. View Pacira Pharmaceuticals' Earnings History.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2017?

14 brokerages have issued 1-year target prices for Pacira Pharmaceuticals' stock. Their predictions range from $36.00 to $87.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $56.00 in the next twelve months. View Analyst Ratings for Pacira Pharmaceuticals.

What are analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
  • 2. According to Zacks Investment Research, "The company’s efforts to expand Exparel's label to boost sales in oral surgery and chronic pain are encouraging. The company reported positive topline results for Exparel from its phase IV study in total knee arthroplasty (TKA). The company also collaborated with DePuy Synthes which is expected to significantly expand use of Exparel across a broad range of surgical procedures. Pacira is looking to expand Exparel's label in the animal health market as well. Its share price has underperformed the broader industry in the past one year. However, Pacira’s sole dependence on Exparel for top-line growth is concerning. We are also concerned about the lack of other late-stage candidates in the company’s pipeline. Estimate movement has been mixed lately ahead of the Q1 earnings results. Pacira has a positive record of earnings surprises in recent quarters." (5/2/2017)
  • 3. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:

  • David M. Stack, Chairman of the Board, Chief Executive Officer
  • Charles A. Reinhart III, Chief Financial Officer
  • Scott N. Braunstein M.D., Senior Vice President - Strategy and Corporate Development
  • James B. Jones M.D., Senior Vice President, Chief Medical Officer
  • Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary
  • Robert J. Weiland, Chief Commercial Officer
  • Mark Froimson, Director
  • Gary Pace Ph.D., Director
  • Laura A. Brege, Independent Director
  • Yvonne L. Greenstreet M.D., Independent Director

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.89%), Bank of Montreal Can (0.08%), Mizuho Securities USA LLC (0.02%), Malaga Cove Capital LLC (0.02%), Fisher Asset Management LLC (0.02%) and US Bancorp DE (0.01%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, US Bancorp DE and Peregrine Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals stock in the last year include David M Stack, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

Who bought Pacira Pharmaceuticals stock? Who is buying Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Malaga Cove Capital LLC. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include James B Jones, James S Scibetta, John P Phd Longenecker and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $48.70.

MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  475 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  676
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $56.00 (14.99% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/19/2017WedbushReiterated RatingOutperform$87.00LowView Rating Details
7/14/2017Cowen and CompanyReiterated RatingHoldLowView Rating Details
6/27/2017Royal Bank Of CanadaSet Price TargetBuy$58.00N/AView Rating Details
5/22/2017Canaccord GenuitySet Price TargetBuy$60.00MediumView Rating Details
5/6/2017HC WainwrightSet Price TargetBuy$59.00LowView Rating Details
5/5/2017MizuhoLower Price TargetBuy -> Buy$57.00 -> $54.00MediumView Rating Details
4/4/2017Jefferies Group LLCSet Price TargetBuy$60.00MediumView Rating Details
3/21/2017Barclays PLCReiterated RatingOverweight -> Overweight$54.00 -> $59.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingMarket PerformHighView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$60.00MediumView Rating Details
3/2/2017Janney Montgomery ScottDowngradeNeutral -> Sell$38.00N/AView Rating Details
3/2/2017BMO Capital MarketsReiterated RatingHold$45.00N/AView Rating Details
12/1/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Neutral$36.00N/AView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
1/29/2016Bank of America CorporationUpgradeNeutral -> Buy$75.00N/AView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Earnings History by Quarter for Pacira Pharmaceuticals (NASDAQ PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Ownership Percentage: 6.60%
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017David M StackCEOSell4,311$43.32$186,752.52View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.12View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.64View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.76View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.00View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.26View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.00View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pacira Pharmaceuticals (NASDAQ:PCRX)
Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline logoPacira Pharmaceuticals, Inc. (PCRX) Given Outperform Rating at Wedbush - July 19 at 8:54 AM logo4 Small-Cap Stocks Set to Grow EPS by at Least 400% Through 2020 - July 18 at 7:11 AM logoETFs with exposure to Pacira Pharmaceuticals, Inc. : July 17, 2017 - July 18 at 7:11 AM logoPacira Pharmaceuticals Inc (PCRX) Stock Rating Reaffirmed by Cowen and Company - July 14 at 5:34 PM logoNotable Thursday Option Activity: TGT, MCO, PCRX - July 14 at 7:20 AM logo$74.57 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter - July 12 at 11:42 AM logo-$0.27 Earnings Per Share Expected for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) This Quarter - July 10 at 8:21 AM logoETFs with exposure to Pacira Pharmaceuticals, Inc. : July 6, 2017 - July 7 at 7:59 AM logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Upgraded at BidaskClub - July 5 at 6:20 PM logoPacira Pharmaceuticals, Inc. (PCRX) Given Average Recommendation of "Hold" by Analysts - July 3 at 11:24 AM logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : June 22, 2017 - June 22 at 8:30 AM logoPacira Pharmaceuticals' (PCRX) Outperform Rating Reiterated at Wedbush - June 21 at 7:42 AM logoPacira Pharmaceuticals Inc (PCRX) Upgraded to Hold at ValuEngine - June 20 at 11:40 PM logoPacira Pharmaceuticals, Inc. (PCRX) Expected to Post Quarterly Sales of $74.57 Million - June 16 at 5:49 PM logoPacira Pharma (PCRX) Appoints Mark Froimson to Board of Directors - - June 16 at 8:47 AM logoPacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors - June 16 at 8:47 AM logoPacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference - June 14 at 8:55 AM logoZacks: Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Earnings of -$0.27 Per Share - June 14 at 8:11 AM logoWhy Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report? - June 9 at 7:23 PM logoInsider Selling: Pacira Pharmaceuticals Inc (PCRX) CAO Sells 1,877 Shares of Stock - June 7 at 11:16 PM logoPacira Pharmaceuticals Inc (PCRX) VP Lauren Bullaro Riker Sells 601 Shares - June 7 at 8:21 PM logoJames S. Scibetta Sells 1,966 Shares of Pacira Pharmaceuticals Inc (PCRX) Stock - June 7 at 8:20 PM logoScott Braunstein Sells 768 Shares of Pacira Pharmaceuticals Inc (PCRX) Stock - June 7 at 8:20 PM logoPacira Pharmaceuticals Inc (PCRX) CEO David M. Stack Sells 4,311 Shares - June 7 at 7:50 PM logoPacira Pharmaceuticals Inc (PCRX) Given Consensus Recommendation of "Hold" by Brokerages - June 6 at 10:54 AM logoPacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference - June 1 at 7:57 PM logoPacira Pharmaceuticals Inc (PCRX) Receives "Buy" Rating from Canaccord Genuity - May 29 at 9:02 AM logoOpioids are still the best pain drug we’ve got - May 26 at 8:24 PM logoPacira Pharmaceuticals Announces Resignation of James Scibetta - GlobeNewswire (press release) - May 25 at 5:28 AM logoWedbush Reaffirms Outperform Rating for Pacira Pharmaceuticals Inc (PCRX) - May 24 at 11:32 AM logoPacira Pharmaceuticals Inc (PCRX) Given a $60.00 Price Target at Canaccord Genuity - May 23 at 9:58 PM logoPacira Pharma (PCRX) President, James Scibetta Confirms Resignation - May 23 at 6:37 PM logoPacira Pharmaceuticals Announces Resignation of James Scibetta - May 23 at 6:37 PM logoETFs with exposure to Pacira Pharmaceuticals, Inc. : May 22, 2017 - May 22 at 6:19 PM logoPacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 11:55 AM logoPacira Pharmaceuticals Inc (PCRX) President Sells $1,024,000.00 in Stock - May 17 at 10:29 PM logoPacira Pharmaceuticals Inc (PCRX) CAO Kristen Marie Williams Sells 21,041 Shares - May 17 at 10:29 PM logoZacks: Analysts Expect Pacira Pharmaceuticals Inc (PCRX) to Announce -$0.27 Earnings Per Share - May 17 at 10:28 AM logoPacira Pharmaceuticals Inc (PCRX) Given a $58.00 Price Target by Royal Bank of Canada Analysts - May 15 at 3:14 PM logoPacira Pharmaceuticals Inc (PCRX) Receives Consensus Rating of "Hold" from Analysts - May 12 at 11:45 AM logoPacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - May 10 at 11:45 AM logoPacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : May 8, 2017 - May 8 at 12:06 PM logoMizuho Trims Pacira Pharmaceuticals Inc (PCRX) Target Price to $54.00 - May 6 at 3:22 PM logoPacira Pharmaceuticals' (PCRX) "Buy" Rating Reaffirmed at Canaccord Genuity - May 5 at 9:34 PM logoEdited Transcript of PCRX earnings conference call or presentation 4-May-17 12:30pm GMT - May 5 at 8:45 AM logoPacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results - Yahoo Finance - May 5 at 12:23 AM logoPacira Pharmaceuticals (PCRX) Q1 2017 Results - Earnings Call Transcript - May 4 at 7:21 PM logoPacira Pharmaceuticals Inc (PCRX) Announces Earnings Results, Misses Expectations By $0.17 EPS - May 4 at 5:24 PM logoPacira reports 1Q loss - May 4 at 8:45 AM logoPacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results - GlobeNewswire (press release) - May 4 at 8:06 AM



Pacira Pharmaceuticals (PCRX) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff